A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Jeffrey Crawford, MD, Paul Swanson, MD, Paul Schwarzenberger, MD, Alan Sandler, MD, Diane Prager, MD, Kathy Zhang, PhD, Daniel J. Freeman, PhD, Carol W. Johnson, DVM, PhD, Kartik Krishnan, MD, PhD, David Johnson, MD Journal of Thoracic Oncology Volume 8, Issue 12, Pages 1510-1518 (December 2013) DOI: 10.1097/JTO.0b013e3182a7d1da Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 1 CONSORT diagram for part 2. Journal of Thoracic Oncology 2013 8, 1510-1518DOI: (10.1097/JTO.0b013e3182a7d1da) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 2 Time to disease progression in part 2. CI, confidence interval; C/P, carboplatin/paclitaxel. Journal of Thoracic Oncology 2013 8, 1510-1518DOI: (10.1097/JTO.0b013e3182a7d1da) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 3 Median (A) progression-free survival and (B) median overall survival in part 2. CI, confidence interval; C/P, carboplatin/paclitaxel. Journal of Thoracic Oncology 2013 8, 1510-1518DOI: (10.1097/JTO.0b013e3182a7d1da) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions